X-linked adrenoleukodystrophy: clinical, biochemical and pathogenetic aspects

Area of Science:

• Genetics and Molecular Biology
• Neurology
• Metabolic Disorders

Background:

• X-linked adrenoleukodystrophy (X-ALD) is a rare genetic disorder with diverse clinical presentations.
• It arises from mutations in the ABCD1 gene, affecting peroxisomal very long-chain fatty acid (VLCFA) transport.
• Accumulation of VLCFAs is a hallmark diagnostic marker for X-ALD.

Purpose of the Study:

• To summarize the current understanding of X-ALD's molecular basis, pathogenesis, and therapeutic landscape.
• To highlight the challenges in interpreting animal model data due to species differences.
• To underscore the urgent need for novel therapeutic strategies beyond current treatments.

Main Methods:

• Review of existing literature on X-ALD genetics, molecular defects, and clinical manifestations.
• Analysis of data from X-ALD mouse models and consideration of species-specific differences.
• Evaluation of current treatment options and emerging therapeutic approaches.

Main Results:

• The primary defect in X-ALD involves mutations in the ABCD1 gene, leading to impaired ALDP function and VLCFA accumulation.
• Pathogenesis is complex, involving inflammatory demyelination and neurodegeneration, influenced by genetic and environmental factors.
• Bone marrow transplantation is effective for childhood cerebral X-ALD but requires early intervention.

Conclusions:

• X-ALD pathogenesis is multifactorial, necessitating a deeper understanding for effective treatment development.
• Current treatments are limited, emphasizing the critical need for innovative therapies like gene therapy and dietary interventions.
• Further research is crucial to overcome challenges posed by species differences in X-ALD models.